An update on novel mechanisms of primary aldosteronism

Journal of Endocrinology

Volumn 224, Issue 2, 2015, Pages R63-R77

  Zennaro, Maria Christina ^a,b,c   Boulkroun, Sheerazed ^a,b   Fernandes Rosa, Fabio ^a,b,c  

^a PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Aldosterone producing adenoma; ATpase; Bilateral adrenal hyperplasia; Calcium channels; Endocrine tumor; Genetic susceptibility; Genotype phenotype correlation; Phenotypic variability; Potassium channels; Primary aldosteronism; Somatic mutations

Indexed keywords

ALDOSTERONE; CACNA1D PROTEIN, HUMAN; CALCIUM CHANNEL L TYPE; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; KCNJ5 PROTEIN, HUMAN;

ADRENAL HYPERPLASIA; ARTICLE; CACNA1D GENE; CELL PROLIFERATION; FAMILIAL DISEASE; FAMILIAL HYPERALDOSTERONISM TYPE 1; FAMILIAL HYPERALDOSTERONISM TYPE II; FAMILIAL HYPERALDOSTERONISM TYPE III; GERMLINE MUTATION; HUMAN; HYPERALDOSTERONISM; KCNJ5 GENE; PATIENT CARE; PHENOTYPE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; SOMATIC MUTATION; ADRENAL CORTEX ADENOMA; ADRENAL CORTEX TUMOR; ANIMAL; CLASSIFICATION; ECTOPIC HORMONE PRODUCTION; GENETICS; METABOLISM;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL ADENOMA; ALDOSTERONE; ANIMALS; CALCIUM CHANNELS, L-TYPE; G PROTEIN-COUPLED INWARDLY-RECTIFYING POTASSIUM CHANNELS; GERM-LINE MUTATION; HUMANS; HYPERALDOSTERONISM; PARANEOPLASTIC ENDOCRINE SYNDROMES;

EID: 84921341535     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-14-0597     Document Type: Article

References (100)

1. Adachi M, Muroya K, Asakura Y, Sugiyama K, Homma K & Hasegawa T 2014 Discordant genotype-phenotype correlation in familial hyper-aldosteronism type III with KCNJ5 gene mutation: a patient report and review of the literature. Hormone Research in Pædiatrics 82 138-142. (doi:10.1159/000358197)
2. Aglony M, Martinez-Aguayo A, Carvajal CA, Campino C, Garcia H, Bancalari R, Bolte L, Avalos C, Loureiro C, Trejo P et al. 2011 Frequency of familial hyperaldosteronism type 1 in a hypertensive pediatric population: clinical and biochemical presentation. Hypertension 57 1117-1121. (doi:10.1161/HYPERTENSIONAHA.110.168740)
3. Akerstrom T, Crona J, Delgado Verdugo A, Starker LF, Cupisti K, Willenberg HS, Knoefel WT, Saeger W, Feller A, Ip J et al. 2012 Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity filter. PLoS ONE 7 e41926. (doi:10.1371/journal.pone.0041926)
4. Aritomi S, Konda T & Yoshimura M 2012 L/N-type calcium channel blocker suppresses reflex aldosterone production induced by antihypertensive action. Heart and Vessels 27 419-423. (doi:10.1007/s00380-011-0191-8)
5. Azizan EA, Lam BY, Newhouse SJ, Zhou J, Kuc RE, Clarke J, Happerfield L, Marker A, Hoffman GJ & Brown MJ 2012 Microarray, qPCR, and KCNJ5 sequencing of APAs reveal differences in genotype and phenotype between zona glomerulosa-and zona fasciculata-like tumors. Journal of Clinical Endocrinology and Metabolism 97 E819-E829. (doi:10.1210/jc.2011-2965)
6. Azizan EA, Poulsen H, Tuluc P, Zhou J, Clausen MV, Lieb A, Maniero C, Garg S, Bochukova EG, Zhao W et al. 2013 Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nature Genetics 45 1055-1060. (doi:10.1038/ng.2716)
7. Ballantine DM, Klemm SA, Tunny TJ, Stowasser M & Gordon RD 1996a PCR-SSCP analysis of the p53 gene in tumours of the adrenal gland. Clinical and Experimental Pharmacology & Physiology 23 582-583. (doi:10.1111/j.1440-1681.1996.tb02786.x)
8. Ballantine DM, Klemm SA, Tunny TJ, Stowasser M & Gordon RD 1996b PCR-SSCP analysis of the promoter region of the renin gene in patients with aldosterone-producing adenomas. Clinical and Experimental Pharmacology & Physiology 23 584-586. (doi:10.1111/j.1440-1681.1996.tb02787.x)
9. Bandulik S, Penton D, Barhanin J & Warth R 2010 TASK1 and TASK3 potassium channels: determinants of aldosterone secretion and adrenocortical zonation. Hormone and Metabolic Research 42 450-457. (doi:10.1055/s-0029-1243601)
10. Bandulik S, Tauber P, Penton D, Schweda F, Tegtmeier I, Sterner C, Lalli E, Lesage F, Hartmann M, Barhanin J et al. 2013 Severe hyperaldo-steronism in neonatal Task3 potassium channel knockout mice is associated with activation of the intraadrenal renin-angiotensin system. Endocrinology 154 2712-2722. (doi:10.1210/en.2013-1101)
11. Berthon A, Sahut-Barnola I, Lambert-Langlais S, de Joussineau C, Damon-Soubeyrand C, Louiset E, Taketo MM, Tissier F, Bertherat J, Lefrancois-Martinez AM et al. 2010 Constitutive b-catenin activation induces adrenal hyperplasia and promotes adrenal cancer develop-ment. Human Molecular Genetics 19 1561-1576. (doi:10.1093/hmg/ddq029)
12. Berthon A, Drelon C, Ragazzon B, Boulkroun S, Tissier F, Amar L, Samson-Couterie B, Zennaro MC, Plouin PF, Skah S et al. 2014 WNT/b-catenin signalling is activated in aldosterone-producing adenomas and controls aldosterone production. Human Molecular Genetics 23 889-905. (doi:10.1093/hmg/ddt484)
13. Beuschlein F, Boulkroun S, Osswald A, Wieland T, Nielsen HN, Lichtenauer UD, Penton D, Schack VR, Amar L, Fischer E et al. 2013 Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nature Genetics 45 440-444. (doi:10.1038/ng.2550)
14. Boulkroun S, Samson-Couterie B, Dzib JF, Lefebvre H, Louiset E, Amar L, Plouin PF, Lalli E, Jeunemaitre X, Benecke A et al. 2010 Adrenal cortex remodeling and functional zona glomerulosa hyperplasia in primary aldosteronism. Hypertension 56 885-892. (doi:10.1161/HYPERTENSIO-NAHA.110.158543)
15. Boulkroun S, Samson-Couterie B, Golib-Dzib JF, Amar L, Plouin PF, Sibony M, Lefebvre H, Louiset E, Jeunemaitre X, Meatchi T et al. 2011 Aldosterone-producing adenoma formation in the adrenal cortex involves expression of stem/progenitor cell markers. Endocrinology 152 4753-4763. (doi:10.1210/en.2011-1205)
16. Boulkroun S, Beuschlein F, Rossi GP, Golib-Dzib JF, Fischer E, Amar L, Mulatero P, Samson-Couterie B, Hahner S, Quinkler M et al. 2012 Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension 59 592-598. (doi:10.1161/HYPERTENSIONAHA.111.186478)
17. Boulkroun S, Golib Dzib JF, Samson-Couterie B, Rosa FL, Rickard AJ, Meatchi T, Amar L, Benecke A & Zennaro MC 2013 KCNJ5 mutations in aldosterone producing adenoma and relationship with adrenal cortex remodeling. Molecular and Cellular Endocrinology 371 221-227. (doi:10.1016/j.mce.2013.01.018)
18. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB & Weissmann P 2002 Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 40 892-896. (doi:10.1161/01.HYP. 0000040261.30455.B6)
19. Carvajal CA, Campino C, Martinez-Aguayo A, Tichauer JE, Bancalari R, Valdivia C, Trejo P, Aglony M, Baudrand R, Lagos CF et al. 2012 A new presentation of the chimeric CYP11B1/CYP11B2 gene with low prevalence of primary aldosteronism and atypical gene segregation pattern. Hypertension 59 85-91. (doi:10.1161/HYPERTENSIONAHA. 111.180513)
20. Charmandari E, Sertedaki A, Kino T, Merakou C, Hoffman DA, Hatch MM, Hurt DE, Lin L, Xekouki P, Stratakis CA et al. 2012 A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension. Journal of Clinical Endocrinology and Metabolism 97 E1532-E1539. (doi:10.1210/jc.2012-1334)
21. Choi M, Scholl UI, Yue P, Bjorklund P, Zhao B, Nelson-Williams C, Ji W, Cho Y, Patel A, Men CJ et al. 2011 KC channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 331 768-772. (doi:10.1126/science.1198785)
22. Davies E, Bonnardeaux A, Plouin PF, Corvol P & Clauser E 1997 Somatic mutations of the angiotensin II (AT1) receptor gene are not present in aldosterone-producing adenoma. Journal of Clinical Endocrinology and Metabolism 82 611-615.
23. Davies LA, Hu C, Guagliardo NA, Sen N, Chen X, Talley EM, Carey RM, Bayliss DA & Barrett PQ 2008 TASK channel deletion in mice causes primary hyperaldosteronism. PNAS 105 2203-2208. (doi:10.1073/pnas.0712000105)
24. Dekkers T, ter Meer M, Lenders JW, Hermus AR, Schultze Kool L, Langenhuijsen JF, Nishimoto K, Ogishima T, Mukai K, Azizan EA et al. 2014 Adrenal nodularity and somatic mutations in primary aldoster-onism: one node is the culprit?. Journal of Clinical Endocrinology and Metabolism 99 E1341-E1351. (doi:10.1210/jc.2013-4255)
25. Dluhy RG & Lifton RP 1995 Glucocorticoid-remediable aldosteronism (GRA): diagnosis, variability of phenotype and regulation of potassium homeostasis. Steroids 60 48-51. (doi:10.1016/0039-128X(94)00010-A)
26. Doi M, Takahashi Y, Komatsu R, Yamazaki F, Yamada H, Haraguchi S, Emoto N, Okuno Y, Tsujimoto G, Kanematsu A et al. 2010 Salt-sensitive hypertension in circadian clock-deficient Cry-null mice involves dysregulated adrenal Hsd3b6. Nature Medicine 16 67-74. (doi:10.1038/nm.2061)
27. Doi M, Satoh F, Maekawa T, Nakamura Y, Fustin JM, Tainaka M, Hotta Y, Takahashi Y, Morimoto R, Takase K et al. 2014 Isoform-specific monoclonal antibodies against 3b-hydroxysteroid dehydrogenase/isomerase family provide markers for subclassification of human primary aldosteronism. Journal of Clinical Endocrinology and Metabolism 99 E257-E262. (doi:10.1210/jc.2013-3279)
28. Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N, Papadopoulos N, Vogiatzis K & Zamboulis C 2008 Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 371 1921-1926. (doi:10.1016/S0140-6736(08)60834-X)
29. Enberg U, Volpe C, Hoog A, Wedell A, Farnebo LO, Thoren M & Hamberger B 2004 Postoperative differentiation between unilateral adrenal adenoma and bilateral adrenal hyperplasia in primary aldosteronism by mRNA expression of the gene CYP11B2. European Journal of Endocrinology 151 73-85. (doi:10.1530/eje.0.1510073)
30. Fardella CE, Pinto M, Mosso L, Gomez-Sanchez C, Jalil J & Montero J 2001 Genetic study of patients with dexamethasone-suppressible aldo-steronism without the chimeric CYP11B1/CYP11B2 gene. Journal of Clinical Endocrinology and Metabolism 86 4805-4807. (doi:10.1210/jcem.86.10.7920)
31. Felizola SJ, Maekawa T, Nakamura Y, Satoh F, Ono Y, Kikuchi K, Aritomi S, Ikeda K, Yoshimura M, Tojo K et al. 2014 Voltage-gated calcium channels in the human adrenal and primary aldosteronism. Journal of Steroid Biochemistry and Molecular Biology 144 Pt B 410-416. (doi:10.1016/j.jsbmb.2014.08.012)
32. Fernandes-Rosa FL, Williams TA, Riester A, Steichen O, Beuschlein F, Boulkroun S, Strom TM, Monticone S, Amar L, Meatchi T et al. 2014 Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma. Hypertension 64 354-361. (doi:10.1161/HYPERTENSIONAHA.114.03419)
33. Freel EM, Mark PB, Weir RA, McQuarrie EP, Allan K, Dargie HJ, McClure JD, Jardine AG, Davies E & Connell JM 2012 Demonstration of blood pressure-independent noninfarct myocardial fibrosis in primary aldosteronism: a cardiac magnetic resonance imaging study. Circulation. Cardiovascular Imaging 5 740-747. (doi:10.1161/CIRCIMA-GING.112.974576)
34. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF Jr.& Montori VM 2008 Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 93 3266-3281. (doi:10.1210/jc.2008-0104)
35. Gates LJ, Benjamin N, Haites NE, MacConnachie AA & McLay JS 2001 Is random screening of value in detecting glucocorticoid-remediable aldosteronism within a hypertensive population?. Journal of Human Hypertension 15 173-176. (doi:10.1038/sj.jhh.1001152)
36. Geller DS, Zhang J, Wisgerhof MV, Shackleton C, Kashgarian M & Lifton RP 2008 A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. Journal of Clinical Endo-crinology and Metabolism 93 3117-3123. (doi:10.1210/jc.2008-0594)
37. Gomez-Sanchez CE 2014 Channels and pumps in aldosterone-producing adenomas. Journal of Clinical Endocrinology and Metabolism 99 1152-1156. (doi:10.1210/jc.2014-1062)
38. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Finn WL & Krek AL 1991 Clinical and pathological diversity of primary aldosteronism, including a new familial variety. Clinical and Experimental Pharmacology & Physiology 18 283-286. (doi:10.1111/j.1440-1681.1991.tb01446.x)
39. Guagliardo NA, Yao J, Hu C & Barrett PQ 2012a Minireview: aldosterone biosynthesis: electrically gated for our protection. Endocrinology 153 3579-3586. (doi:10.1210/en.2012-1339)
40. Guagliardo NA, Yao J, Hu C, Schertz EM, Tyson DA, Carey RM, Bayliss DA & Barrett PQ 2012b TASK-3 channel deletion in mice recapitulates low-renin essential hypertension. Hypertension 59 999-1005. (doi:10.1161/HYPERTENSIONAHA.111.189662)
41. Hannemann A & Wallaschofski H 2012 Prevalence of primary aldosteron-ism in patient's cohorts and in population-based studies - a review of the current literature. Hormone and Metabolic Research 44 157-162. (doi:10.1055/s-0031-1295438)
42. Heitzmann D, Derand R, Jungbauer S, Bandulik S, Sterner C, Schweda F, El Wakil A, Lalli E, Guy N, Mengual R et al. 2008 Invalidation of TASK1 potassium channels disrupts adrenal gland zonation and mineralo-corticoid homeostasis. EMBO Journal 27 179-187. (doi:10.1038/sj. emboj.7601934)
43. Jackson RV, Lafferty A, Torpy DJ & Stratakis C 2002 New genetic insights in familial hyperaldosteronism. Annals of the New York Academy of Sciences 970 77-88. (doi:10.1111/j.1749-6632.2002.tb04414.x)
44. Jeske YW, So A, Kelemen L, Sukor N, Willys C, Bulmer B, Gordon RD, Duffy D & Stowasser M 2008 Examination of chromosome 7p22 candidate genes RBaK, PMS2 and GNA12 in familial hyperaldosteronism type II. Clinical and Experimental Pharmacology & Physiology 35 380-385. (doi:10.1111/j.1440-1681.2008.04882.x)
45. Jin W, Klem AM, Lewis JH & Lu Z 1999 Mechanisms of inward-rectifier KC channel inhibition by tertiapin-Q. Biochemistry 38 14294-14301. (doi:10.1021/bi991206j)
46. Kitamoto T, Suematsu S, Matsuzawa Y, Saito J, Omura M & Nishikawa T 2014 Comparison of cardiovascular complications in patients with and without KCNJ5 gene mutations harboring aldosterone-producing adenomas. Journal of Atherosclerosis and Thrombosis 21 [in press]. (doi:10.5551/jat.24455)
47. Lafferty AR, Torpy DJ, Stowasser M, Taymans SE, Lin JP, Huggard P, Gordon RD & Stratakis CA 2000 A novel genetic locus for low renin hypertension: familial hyperaldosteronism type II maps to chromo-some 7 (7p22). Journal of Medical Genetics 37 831-835. (doi:10.1136/jmg.37.11.831)
48. Lenzini L, Seccia TM, Aldighieri E, Belloni AS, Bernante P, Giuliani L, Nussdorfer GG, Pessina AC & Rossi GP 2007 Heterogeneity of aldosterone-producing adenomas revealed by a whole transcriptome analysis. Hypertension 50 1106-1113. (doi:10.1161/HYPERTENSIO-NAHA.107.100438)
49. Lenzini L, Caroccia B, Campos AG, Fassina A, Belloni AS, Seccia TM, Kuppusamy M, Ferraro S, Skander G, Bader M et al. 2014 Lower expression of the TWIK-related acid-sensitive KC channel 2 (TASK-2) gene is a hallmark of aldosterone-producing adenoma causing human primary aldosteronism. Journal of Clinical Endocrinology and Metabolism 99 E674-E682. (doi:10.1210/jc.2013-2900)
50. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S & Lalouel JM 1992 A chimaeric 11b-hydroxylase aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355 262-265. (doi:10.1038/355262a0)
51. Litchfield WR, Anderson BF, Weiss RJ, Lifton RP & Dluhy RG 1998 Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension 31 445-450. (doi:10.1161/01. HYP.31.1.445)
52. Medeau V, Assie G, Zennaro MC, Clauser E, Plouin PF & Jeunemaitre X 2005a Familial aspect of primary hyperaldosteronism: analysis of families compatible with primary hyperaldosteronism type 2. Annales d'Endocrinologie 66 240-246. (doi:10.1016/S0003-4266(05)81756-1)
53. Medeau V, AssiéG, Zennaro M-C, Clauser E, Plouin P-F & Jeunemaitre X 2005b Familial aspects of primary aldosteronism: investigation of possible FH1 families. Annales d'Endocrinologie 66 1-7. (doi:10.1016/S0003-4266(05)81756-1)
54. Monticone S, Hattangady NG, Nishimoto K, Mantero F, Rubin B, Cicala MV, Pezzani R, Auchus RJ, Ghayee HK, Shibata H et al. 2012 Effect of KCNJ5 mutations on gene expression in aldosterone-producing adenomas and adrenocortical cells. Journal of Clinical Endocrinology and Metabolism 97 E1567-E1572. (doi:10.1210/jc. 2011-3132)
55. Monticone S, Hattangady NG, Penton D, Isales CM, Edwards MA, Williams TA, Sterner C, Warth R, Mulatero P & Rainey WE 2013 A novel Y152C KCNJ5 mutation responsible for familial hyperaldosteronism type III. Journal of Clinical Endocrinology and Metabolism 98 E1861-E1865. (doi:10.1210/jc.2013-2428)
56. Monticone S, Else T, Mulatero P, Williams TA & Rainey WE 2014 Understanding primary aldosteronism: impact of next generation sequencing and expression profiling. Molecular and Cellular Endocrinology 399C 311-320. (doi:10.1016/j.mce.2014.09.015)
57. Mulatero P, Tizzani D, Viola A, Bertello C, Monticone S, Mengozzi G, Schiavone D, Williams TA, Einaudi S, La Grotta A et al. 2011 Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (primary aldosteronism in Torino-genetic forms). Hypertension 58 797-803. (doi:10.1161/HYPERTENSIONAHA.111.175083)
58. Mulatero P, Tauber P, Zennaro MC, Monticone S, Lang K, Beuschlein F, Fischer E, Tizzani D, Pallauf A, Viola A et al. 2012 KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyper-aldosteronism. Hypertension 59 235-240. (doi:10.1161/HYPERTENSIO-NAHA.111.183996)
59. Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A, Crudo V, Burrello J, Milan A, Rabbia F et al. 2013 Long-term cardio-and cerebrovascular events in patients with primary aldosteronism. Journal of Clinical Endocrinology and Metabolism 98 4826-4833. (doi:10.1210/jc.2013-2805)
60. Murthy M, Xu S, Massimo G, Wolley M, Gordon RD, Stowasser M & O'Shaughnessy KM 2014 Role for germline mutations and a rare coding single nucleotide polymorphism within the KCNJ5 potassium channel in a large cohort of sporadic cases of primary aldosteronism. Hypertension 63 783-789. (doi:10.1161/HYPERTENSIONAHA.113. 02234)
61. Nakamura Y, Maekawa T, Felizola SJ, Satoh F, Qi X, Velarde-Miranda C, Plonczynski MW, Ise K, Kikuchi K, Rainey WE et al. 2014 Adrenal CYP11B1/2 expression in primary aldosteronism: immunohistochem-ical analysis using novel monoclonal antibodies. Molecular and Cellular Endocrinology 392 73-79. (doi:10.1016/j.mce.2014.05.002)
62. Nanba K, Tsuiki M, Sawai K, Mukai K, Nishimoto K, Usui T, Tagami T, Okuno H, Yamamoto T, Shimatsu A et al. 2013 Histopathological diagnosis of primary aldosteronism using CYP11B2 immuno-histochemistry. Journal of Clinical Endocrinology and Metabolism 98 1567-1574. (doi:10.1210/jc.2012-3726)
63. New M 1980 Hypertension of childhood with suppressed renin. Endocrine Reviews 1 421-430. (doi:10.1210/edrv-1-4-421)
64. Nishimoto K, Nakagawa K, Li D, Kosaka T, Oya M, Mikami S, Shibata H, Itoh H, Mitani F, Yamazaki T et al. 2010 Adrenocortical zonation in humans under normal and pathological conditions. Journal of Clinical Endocrinology and Metabolism 95 2296-2305. (doi:10.1210/jc.2009-2010)
65. Oki K, Plonczynski MW, Luis Lam M, Gomez-Sanchez EP & Gomez-Sanchez CE 2012a Potassium channel mutant KCNJ5 T158A expression in HAC-15 cells increases aldosterone synthesis. Endocrinology 153 1774-1782. (doi:10.1210/en.2011-1733)
66. Oki K, Plonczynski M, Lam M, Gomez-Sanchez E & Gomez-Sanchez C 2012b The potassium channel, Kir3.4 participates in angiotensin II-stimulated aldosterone production by a human adrenocortical cell line. Endocrinology 153 4328-4335. (doi:10.1210/en.2012-1241)
67. Ono Y, Nakamura Y, Maekawa T, Felizola SJ, Morimoto R, Iwakura Y, Kudo M, Seiji K, Takase K, Arai Y et al. 2014 Different expression of 11b-hydroxylase and aldosterone synthase between aldosterone-producing microadenomas and macroadenomas. Hypertension 64 438-444. (doi:10.1161/HYPERTENSIONAHA.113.02944)
68. Osswald A, Fischer E, Degenhart C, Quinkler M, Bidlingmaier M, Pallauf A, Lang K, Mussack T, Hallfeldt K, Beuschlein F et al. 2013 Lack of influence of somatic mutations on steroid gradients during adrenal vein sampling in aldosterone-producing adenoma patients. European Journal of Endocrinology 169 657-663. (doi:10.1530/EJE-13-0551)
69. Pallauf A, Schirpenbach C, Zwermann O, Fischer E, Morak M, Holinski-Feder E, Hofbauer L, Beuschlein F & Reincke M 2012 The prevalence of familial hyperaldosteronism in apparently sporadic primary aldoster-onism in Germany: a single center experience. Hormone and Metabolic Research 44 215-220. (doi:10.1055/s-0031-1299730)
70. Pardo-Manuel de Villena F & Sapienza C 2001a Nonrandom segregation during meiosis: the unfairness of females. Mammalian Genome 12 331-339. (doi:10.1007/s003350040003)
71. Pardo-Manuel de Villena F & Sapienza C 2001b Transmission of robertsonian chromosomes through human female meiosis. Cytogenetics and Cell Genetics 92 342-344. (doi:10.1159/000056925)
72. Penton D, Bandulik S, Schweda F, Haubs S, Tauber P, Reichold M, Cong LD, El Wakil A, Budde T, Lesage F et al. 2012 Task3 potassium channel gene invalidation causes low renin and salt-sensitive arterial hypertension. Endocrinology 153 4740-4748. (doi:10.1210/en.2012-1527)
73. Pizzolo F, Trabetti E, Guarini P, Mulatero P, Ciacciarelli A, Blengio GS, Corrocher R & Olivieri O 2005 Glucocorticoid remediable aldoste-ronism (GRA) screening in hypertensive patients from a primary care setting. Journal of Human Hypertension 19 325-327. (doi:10.1038/sj.jhh.1001821)
74. Romero DG, Yanes LL, de Rodriguez AF, Plonczynski MW, Welsh BL, Reckelhoff JF, Gomez-Sanchez EP & Gomez-Sanchez CE 2007 Disabled-2 is expressed in adrenal zona glomerulosa and is involved in aldosterone secretion. Endocrinology 148 2644-2652. (doi:10.1210/en.2006-1509)
75. Rossi GP, Sacchetto A, Pavan E, Palatini P, Graniero GR, Canali C & Pessina AC 1997 Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation 95 1471-1478. (doi:10.1161/01.CIR.95.6.1471)
76. Rossi GP, Bolognesi M, Rizzoni D, Seccia TM, Piva A, Porteri E, Tiberio GA, Giulini SM, Agabiti-Rosei E & Pessina AC 2008 Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. Hypertension 51 1366-1371. (doi:10.1161/HYPERTENSIONAHA.108.111369)
77. Rossi GP, Cesari M, Cuspidi C, Maiolino G, Cicala MV, Bisogni V, Mantero F & Pessina AC 2013 Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension 62 62-69. (doi:10.1161/HYPERTENSIO-NAHA.113.01316)
78. Rossi GP, Cesari M, Letizia C, Seccia TM, Cicala MV, Zinnamosca L, Kuppusamy M, Mareso S, Sciomer S, Iacobone M et al. 2014 KCNJ5 gene somatic mutations affect cardiac remodelling but do not preclude cure of high blood pressure and regression of left ventricular hypertrophy in primary aldosteronism. Journal of Hypertension 32 1514-1521 discussion 1522. (doi:10.1097/HJH.0000000000000186)
79. Sakuma I, Suematsu S, Matsuzawa Y, Saito J, Omura M, Maekawa T, Nakamura Y, Sasano H & Nishikawa T 2013 Characterization of steroidogenic enzyme expression in aldosterone-producing adenoma: a comparison with various human adrenal tumors. Endocrine Journal 60 329-336. (doi:10.1507/endocrj.EJ12-0270)
80. Savard S, Amar L, Plouin PF & Steichen O 2013 Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension 62 331-336. (doi:10.1161/HYPERTENSIONAHA.113.01060)
81. Scholl UI, Nelson-Williams C, Yue P, Grekin R, Wyatt RJ, Dillon MJ, Couch R, Hammer LK, Harley FL, Farhi A et al. 2012 Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. PNAS 109 2533-2538. (doi:10.1073/pnas.1121407109)
82. Scholl UI, Goh G, Stolting G, de Oliveira RC, Choi M, Overton JD, Fonseca AL, Korah R, Starker LF, Kunstman JW et al. 2013 Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nature Genetics 45 1050-1054. (doi:10.1038/ng.2695)
83. Seccia TM, Mantero F, Letizia C, Kuppusamy M, Caroccia B, Barisa M, Cicala MV, Miotto D & Rossi GP 2012 Somatic mutations in the KCNJ5 gene raise the lateralization index: implications for the diagnosis of primary aldosteronism by adrenal vein sampling. Journal of Clinical Endocrinology and Metabolism 97 E2307-E2313. (doi:10.1210/jc.2012-2342)
84. So A, Duffy DL, Gordon RD, Jeske YW, Lin-Su K, New MI & Stowasser M 2005 Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity. Journal of Hypertension 23 1477-1484. (doi:10.1097/01.hjh.0000174299.66369.26)
85. So A, Jeske YW, Gordon RD, Duffy D, Kelemen L & Stowasser M 2006 No evidence for coding region mutations in the retinoblastoma-associated Kruppel-associated box protein gene (RBaK) causing familial hyper-aldosteronism type II. Clinical Endocrinology 65 829-831. (doi:10.1111/j.1365-2265.2006.02674.x)
86. Spat A & Hunyady L 2004 Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiological Reviews 84 489-539. (doi:10.1152/physrev.00030.2003)
87. Staermose S, Marwick TH, Gordon RD, Cowley D, Dowling A & Stowasser M 2009 Elevated serum interleukin 6 levels in normotensive individuals with familial hyperaldosteronism type 1. Hypertension 53 e31-e32. (doi:10.1161/HYPERTENSIONAHA.108.128512)
88. Stowasser M 2009 Update in primary aldosteronism. Journal of Clinical Endocrinology and Metabolism 94 3623-3630. (doi:10.1210/jc.2009-1399)
89. Stowasser M & Gordon RD 2000 Primary aldosteronism: learning from the study of familial varieties. Journal of Hypertension 18 1165-1176.
90. Stowasser M & Gordon RD 2001 Familial hyperaldosteronism. Journal of Steroid Biochemistry and Molecular Biology 78 215-229.
91. Stowasser M, Bachmann AW, Huggard PR, Rossetti TR & Gordon RD 2000 Treatment of familial hyperaldosteronism type I: only partial suppres-sion of adrenocorticotropin required to correct hypertension. Journal of Clinical Endocrinology and Metabolism 85 3313-3318. (doi:10.1210/jcem.85.9.6834)
92. Stowasser M, Sharman J, Leano R, Gordon RD, Ward G, Cowley D & Marwick TH 2005 Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldo-steronism type I. Journal of Clinical Endocrinology and Metabolism 90 5070-5076. (doi:10.1210/jc.2005-0681)
93. Sukor N, Mulatero P, Gordon RD, So A, Duffy D, Bertello C, Kelemen L, Jeske Y, Veglio F & Stowasser M 2008 Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families. Journal of Hypertension 26 1577-1582. (doi:10.1097/HJH.0b013e3283028352)
94. Sutherland DJ, Ruse JL & Laidlaw JC 1966 Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Canadian Medical Association Journal 95 1109-1119.
95. Taguchi R, Yamada M, Nakajima Y, Satoh T, Hashimoto K, Shibusawa N, Ozawa A, Okada S, Rokutanda N, Takata D et al. 2012 Expression and mutations of KCNJ5 mRNA in Japanese patients with aldosterone-producing adenomas. Journal of Clinical Endocrinology and Metabolism 97 1311-1319. (doi:10.1210/jc.2011-2885)
96. Tanaka T, Tsutamoto T, Sakai H, Fujii M, Yamamoto T & Horie M 2007 Comparison of the effects of efonidipine and amlodipine on aldoster-one in patients with hypertension. Hypertension Research 30 691-697. (doi:10.1291/hypres.30.691)
97. Tauber P, Penton D, Stindl J, Humberg E, Tegtmeier I, Sterner C, Beuschlein F, Reincke M, Barhanin J, Bandulik S et al. 2014 Pharmacology and pathophysiology of mutated KCNJ5 found in adrenal aldosterone-producing adenomas. Endocrinology 155 1353-1362. (doi:10.1210/en.2013-1944)
98. Volpe C, Hoog A, Ogishima T, Mukai K, Lu M, Thoren M & Hamberger B 2013 Immunohistochemistry improves histopathologic diagnosis in primary aldosteronism. Journal of Clinical Pathology 66 351-354. (doi:10.1136/jclinpath-2012-201287)
99. Williams TA, Monticone S, Crudo V, Warth R, Veglio F & Mulatero P 2012 Visinin-like 1 is upregulated in aldosterone-producing adenomas with KCNJ5 mutations and protects from calcium-induced apoptosis. Hypertension 59 833-839. (doi:10.1161/HYPERTENSIONAHA.111.188532)
100. Williams TA, Monticone S, Schack VR, Stindl J, Burrello J, Buffolo F, Annaratone L, Castellano I, Beuschlein F, Reincke M et al. 2014 Somatic ATP1A1, ATP2B3, and KCNJ5 mutations in aldosterone-producing adenomas. Hypertension 63 188-195. (doi:10.1161/HYPERTENSIO-NAHA.113.01733)